
Bruck Kifle
Examiner (ID: 6836, Phone: (571)272-0668 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1624, 1611, 1622, 1202 |
| Total Applications | 3432 |
| Issued Applications | 2601 |
| Pending Applications | 218 |
| Abandoned Applications | 651 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16253473
[patent_doc_number] => 20200262847
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/867835
[patent_app_country] => US
[patent_app_date] => 2020-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12893
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867835
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/867835 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | May 5, 2020 | Issued |
Array
(
[id] => 16238206
[patent_doc_number] => 20200255440
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => ETHYNYL DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/865233
[patent_app_country] => US
[patent_app_date] => 2020-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4076
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16865233
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/865233 | Ethynyl derivatives | Apr 30, 2020 | Issued |
Array
(
[id] => 16970404
[patent_doc_number] => 11066364
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-20
[patent_title] => NLRX1 ligands
[patent_app_type] => utility
[patent_app_number] => 16/864717
[patent_app_country] => US
[patent_app_date] => 2020-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 65
[patent_no_of_words] => 23096
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864717
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/864717 | NLRX1 ligands | Apr 30, 2020 | Issued |
Array
(
[id] => 16421869
[patent_doc_number] => 20200347067
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/863770
[patent_app_country] => US
[patent_app_date] => 2020-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -47
[patent_words_short_claim] => 5325
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16863770
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/863770 | Tricyclic amine compounds as CDK2 inhibitors | Apr 29, 2020 | Issued |
Array
(
[id] => 19910204
[patent_doc_number] => 12286400
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-29
[patent_title] => Isofagomine salts, methods of use and formulations
[patent_app_type] => utility
[patent_app_number] => 17/605979
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 20503
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605979
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605979 | Isofagomine salts, methods of use and formulations | Apr 23, 2020 | Issued |
Array
(
[id] => 16390929
[patent_doc_number] => 20200331870
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => MCL-1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/857021
[patent_app_country] => US
[patent_app_date] => 2020-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 97713
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857021
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/857021 | MCL-1 inhibitors | Apr 22, 2020 | Issued |
Array
(
[id] => 17702814
[patent_doc_number] => 20220202820
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => USE OF JAK INHIBITORS FOR THE TREATMENT OF PAINFUL CONDITIONS INVOLVING NAV1.7 CHANNELS
[patent_app_type] => utility
[patent_app_number] => 17/604109
[patent_app_country] => US
[patent_app_date] => 2020-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6184
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604109
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/604109 | USE OF JAK INHIBITORS FOR THE TREATMENT OF PAINFUL CONDITIONS INVOLVING NAV1.7 CHANNELS | Apr 14, 2020 | Abandoned |
Array
(
[id] => 16398684
[patent_doc_number] => 20200339542
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/847975
[patent_app_country] => US
[patent_app_date] => 2020-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58431
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16847975
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/847975 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | Apr 13, 2020 | Abandoned |
Array
(
[id] => 17655311
[patent_doc_number] => 20220175776
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS
[patent_app_type] => utility
[patent_app_number] => 17/602355
[patent_app_country] => US
[patent_app_date] => 2020-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 102272
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602355
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/602355 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Apr 7, 2020 | Abandoned |
Array
(
[id] => 16704318
[patent_doc_number] => 10954238
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-03-23
[patent_title] => Substituted naphthyridinone compounds useful as T cell activators
[patent_app_type] => utility
[patent_app_number] => 16/843024
[patent_app_country] => US
[patent_app_date] => 2020-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 183608
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 302
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843024
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/843024 | Substituted naphthyridinone compounds useful as T cell activators | Apr 7, 2020 | Issued |
Array
(
[id] => 17734645
[patent_doc_number] => 20220220104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/600900
[patent_app_country] => US
[patent_app_date] => 2020-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40152
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600900
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/600900 | Pyrazolopyridine compound as RET inhibitor and application thereof | Apr 2, 2020 | Issued |
Array
(
[id] => 16444845
[patent_doc_number] => 10836757
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2020-11-17
[patent_title] => Polymorphic forms of metopimazine
[patent_app_type] => utility
[patent_app_number] => 16/838402
[patent_app_country] => US
[patent_app_date] => 2020-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 24428
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16838402
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/838402 | Polymorphic forms of metopimazine | Apr 1, 2020 | Issued |
Array
(
[id] => 16799107
[patent_doc_number] => 10994023
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-04
[patent_title] => Pyrrolobenzodiazepines and conjugates thereof
[patent_app_type] => utility
[patent_app_number] => 16/837336
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 37993
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16837336
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/837336 | Pyrrolobenzodiazepines and conjugates thereof | Mar 31, 2020 | Issued |
Array
(
[id] => 17953466
[patent_doc_number] => 11479557
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-25
[patent_title] => Inhibitors of the menin-MLL interaction
[patent_app_type] => utility
[patent_app_number] => 16/837421
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 23
[patent_no_of_words] => 74236
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16837421
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/837421 | Inhibitors of the menin-MLL interaction | Mar 31, 2020 | Issued |
Array
(
[id] => 16343478
[patent_doc_number] => 20200308128
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE
[patent_app_type] => utility
[patent_app_number] => 16/835102
[patent_app_country] => US
[patent_app_date] => 2020-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26384
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 228
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16835102
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/835102 | MYC G-quadruplex stabilizing small molecules and their use | Mar 29, 2020 | Issued |
Array
(
[id] => 19931701
[patent_doc_number] => 12304898
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => Quinolyl-containing compound and pharmaceutical composition, and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/594039
[patent_app_country] => US
[patent_app_date] => 2020-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14942
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 488
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594039
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/594039 | Quinolyl-containing compound and pharmaceutical composition, and use thereof | Mar 29, 2020 | Issued |
Array
(
[id] => 16769806
[patent_doc_number] => 10980889
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-04-20
[patent_title] => C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/831579
[patent_app_country] => US
[patent_app_date] => 2020-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68872
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16831579
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/831579 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Mar 25, 2020 | Issued |
Array
(
[id] => 17889833
[patent_doc_number] => 11452780
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-27
[patent_title] => Mtorc1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/828774
[patent_app_country] => US
[patent_app_date] => 2020-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 22
[patent_no_of_words] => 58057
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 701
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828774
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/828774 | Mtorc1 inhibitors | Mar 23, 2020 | Issued |
Array
(
[id] => 17844855
[patent_doc_number] => 11434207
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => P2X4 receptor antagonist
[patent_app_type] => utility
[patent_app_number] => 16/826877
[patent_app_country] => US
[patent_app_date] => 2020-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40493
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 1397
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16826877
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/826877 | P2X4 receptor antagonist | Mar 22, 2020 | Issued |
Array
(
[id] => 17670877
[patent_doc_number] => 20220184044
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => USE OF RIFAXIMIN ON CIRCULATING AGED NEUTROPHILS IN SICKLE CELL DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/441840
[patent_app_country] => US
[patent_app_date] => 2020-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6368
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441840
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/441840 | Use of rifaximin on circulating aged neutrophils in sickle cell disease | Mar 22, 2020 | Issued |